SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as traders await topline survival results from its Phase 3 REGAL trial of galinpepimut-S in AML, after the study reached its 80-event threshold and entered final analysis. Bulls are focused on a potential positive readout and possible short covering, while skeptics stress that the outcome remains uncertain and the stock faces binary trial risk.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after its quarterly report and stronger forward sales outlook, which traders see as evidence of growing AI-computing demand. The reaction is divided: bulls focus on the growth outlook and customer momentum, while bears point to widening losses, heavy spending and profitability concerns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing was pushed to mid-2027 as the company refines assays and continues discussions with the FDA, sparking a sharp selloff. Traders are split between viewing the delay as a fixable manufacturing and testing issue that leaves Phase 3 results intact and worrying about regulatory execution, management credibility, and potential dilution.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos quarterly results beat expectations and the company raised its full-year outlook, with stronger AI infrastructure demand drawing attention. Traders welcomed the results but debated the muted share-price response, with some viewing it as a sell-the-news move or profit-taking despite the stronger guidance.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials quarterly earnings and outlook dominate discussion: traders point to a beat and stronger next-quarter guidance, but debate why shares fell afterward, citing sell-the-news dynamics, options volatility and broader semiconductor weakness despite the positive report.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is attracting attention around its Q3 earnings: traders point to strong revenue growth and improving operating efficiency, while debate centers on a slight earnings miss and worsening loan delinquencies. Bulls see growth and profitability as reassuring; bears are concerned that rising credit risk and a muted share-price reaction temper the results.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Hot inflation data and hawkish Fed-rate expectations have pressured gold as Treasury yields and the dollar strengthened. Traders are divided between expecting further losses after support breaks and buying the dip for a rebound, with some questioning golds safe-haven role amid the selloff.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

A sharp selloff followed Cardinals Q3 results, with traders focused on compressed project margins, withdrawn full-year guidance, and the CFOs planned departure. The community is divided between concerns about management and further deterioration versus dip-buying based on the companys cash position, backlog, and share-repurchase authorization.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs quarterly results, including a revenue beat, margin improvement and a newly authorized share-repurchase program, are driving discussion. Despite the positive report, traders are puzzled by the stocks weakness, debating whether the buyback will translate into actual purchases and whether broader market or rate pressures are outweighing the results.

Flowers Foods, Inc. engages in the production and marketing of packaged bakery foods. It offers breads, buns, rolls, snack items, bagels, English muffins, and tortillas and are sold under a variety of brand names, including Nature’s Own, Dave’s Killer Bread, Wonder, Canyon Bakehouse, Tastykake, and Mrs. Freshley’s. The company was founded by William Howard Flowers, Sr. and Joseph Hampton Flowers, Jr. in 1919 and is headquartered in Thomasville, GA.

Flowers Foods, Inc.

Flowers Foods declining sales and volumes, compressed margins, and lowered outlook have intensified concern about its business trajectory, debt load, and dividend sustainability as shares revisit long-term lows. Traders are split between shorting on fears of further deterioration and buying for value and the dividend, while some speculate about a short squeeze or a Tastykake sale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of -11.69% and -86.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +46.15% and +6.72%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Best Momentum Stocks to Buy for September 17th

MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.

New Strong Buy Stocks for September 17th

MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.

Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Should You Buy Assembly Biosciences (ASMB) After Golden Cross?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

5 Stocks With Recent Price Strength Buoyed by a Strong August

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.


Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going

Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Assembly Biosciences Inc

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Gilead will advance the clinical development and commercialization of the programs and Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option.</li><li>H.C. Wainwright believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."</li><li>According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes.</li></ul>Shares of Assembly Biosciences Inc closed up 3% on Monday after Gilead Sciences exercised the option to license the company’s programs for recurrent genital herpes in a move applauded by Wall Street. &nbsp;The programs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.gilead.com/news/news-details/2025/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes"> include</a> investigational candidates ABI-1179 and ABI-5366. Gilead will advance the clinical development and commercialization of the programs under its ongoing collaboration with Assembly Bio which was inked in 2023 and spans 12 years. Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option and remains eligible for up to $330 million in regulatory and commercial milestones, as well as tiered royalties on net sales.H.C. Wainwright analyst Patrick Trucchio subsequently reiterated a ‘Buy’ rating on Assembly Biosciences (ASMB) with a $50 price target. The analyst believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."<h2 class="st-heading-2">About The Programs</h2>Genital herpes is a common sexually transmitted infection (STI) caused by the herpes simplex virus (HSV), leading to painful blisters and sores around the genitals or anus, though many people have mild or no symptoms and don't know they're infected. Spread through skin-to-skin contact, especially during sex, the virus stays in the body, causing recurring outbreaks triggered by stress, illness, or fatigue.According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes. No new therapies have been approved for HSV in the U.S. or Europe for more than 25 years, the company noted.ABI-1179 and ABI-5366 are novel long-acting inhibitors of viral helicase-primase, an enzyme essential for herpes virus replication. Positive interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated strong antiviral activity and improvements in clinical outcomes, including significant reduction in virus-positive lesions, the company noted. Both compounds also exhibit pharmacokinetic and safety profiles supportive of once-weekly oral dosing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/ASMB"> ASMB </a>rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.Sentiment around GILD stayed within the 'neutral' territory in the meantime.<a href="https://stocktwits.com/symbol/GILD">Shares of GILD</a> have risen nearly 34% this year while ASMB shares have more than doubled.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-rival-ula-ceo-tory-bruno-steps-down/cLeFtcyREub">SpaceX Rival ULA CEO Tory Bruno Steps Down After 12 Years — Says ‘My Work Here Is Now Complete’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.

Gilead Sciences, Inc.

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Current Price	$20.18
Prev Close	$22.37
Open	$22.10
Dividend Yield	0.00%
50-Day Moving Average	$23.88
Beta	1.07
Avg. Volume	222,893.90
PE Ratio	-304.35

52-Week High	$39.71
52-Week Low	$19.20
Market Capitalization	$455.47M
EPS (Annual)	-$0.5461
Price to Book	1.45
Revenue Per Employee	$990,452.06

Feed

News

Sentiment

Earnings

Fundamentals

Info

ASMB Fundamentals